Literature DB >> 6774710

Inhibition of polyamine biosynthesis by alpha-difluoromethyl ornithine potentiates the cytotoxic effects of arabinosyl cytosine in HeLa cells.

P S Sunkara, S K Fowler, K Nishioka, P N Rao.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6774710     DOI： 10.1016/0006-291x(80)90755-x

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN： 0006-291X            Impact factor:   3.575


× No keyword cloud information.
  12 in total

1.  Evaluation of continuous-infusion alpha-difluoromethylornithine therapy for colorectal carcinoma.

Authors:  J A Ajani; D M Ota; V B Grossie; J L Abbruzzese; J S Faintuch; Y Z Patt; D E Jackson; B Levin; K Nishioka
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 2.  The chemotherapeutic potential of polyamine antimetabolites.

Authors:  A N Kingsnorth
Journal:  Ann R Coll Surg Engl       Date:  1986-03       Impact factor: 1.891

3.  Phase I trial and pharmacokinetic study of intravenous and oral alpha-difluoromethylornithine.

Authors:  C A Griffin; M Slavik; S C Chien; J Hermann; G Thompson; O Blanc; G D Luk; S B Baylin; M D Abeloff
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

Review 4.  DNA topoisomerase II as a target of antineoplastic drug therapy.

Authors:  L A Zwelling
Journal:  Cancer Metastasis Rev       Date:  1985       Impact factor: 9.264

5.  Mononuclear cell polyamine content associated with myeloid maturation in patients with leukemia during administration of polyamine inhibitors.

Authors:  A M Maddox; M J Keating; E J Freireich; M K Haddox
Journal:  Invest New Drugs       Date:  1989-07       Impact factor: 3.850

6.  alpha-Difluoromethylornithine inhibits liver metastasis produced by intrasplenic injection of human tumor cells into nude mice.

Authors:  K A Zirvi; K S Dasmahapatra; U Atabek; M A Lyons
Journal:  Clin Exp Metastasis       Date:  1989 Nov-Dec       Impact factor: 5.150

7.  Phase I study of combined alpha interferon, alpha difluoromethylornithine (DFMO), and doxorubicin in advanced malignancy.

Authors:  V Ganju; J H Edmonson; J C Buckner
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

8.  Polyamines in clinical disorders.

Authors:  D F Tierney; L J Marton; A D Hacker; N Lowe
Journal:  West J Med       Date:  1985-01

9.  Alterations in human circulating and bone marrow mononuclear cell polyamine levels in hematologic malignancies as a consequence of difluoromethylornithine administration.

Authors:  A M Maddox; E J Freireich; M J Keating; K F Frasier-Scott; M K Haddox
Journal:  Invest New Drugs       Date:  1988-06       Impact factor: 3.850

10.  Phase I evaluation of intravenous difluoromethylornithine--a polyamine inhibitor.

Authors:  A M Maddox; M J Keating; K E McCredie; E Estey; E J Freireich
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.